Top-Rated StocksTop-RatedNASDAQ:IMCR Immunocore (IMCR) Stock Price, News & Analysis $40.13 -0.02 (-0.05%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$39.27▼$40.8550-Day Range$33.78▼$53.1552-Week Range$33.04▼$76.98Volume161,444 shsAverage Volume609,281 shsMarket Capitalization$2.01 billionP/E RatioN/ADividend YieldN/APrice Target$82.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Immunocore alerts: Email Address Immunocore MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.93 Rating ScoreUpside/Downside106.2% Upside$82.75 Price TargetShort InterestBearish11.95% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.04Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.98) to ($2.26) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.57 out of 5 starsMedical Sector506th out of 936 stocksBiological Products, Except Diagnostic Industry75th out of 154 stocks 4.5 Analyst's Opinion Consensus RatingImmunocore has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 13 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageImmunocore has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Immunocore's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted11.95% of the float of Immunocore has been sold short.Short Interest Ratio / Days to CoverImmunocore has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Immunocore has recently decreased by 1.36%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldImmunocore does not currently pay a dividend.Dividend GrowthImmunocore does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMCR. Previous Next 2.2 News and Social Media Coverage News SentimentImmunocore has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Immunocore this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for IMCR on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Immunocore to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immunocore insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.10% of the stock of Immunocore is held by insiders.Percentage Held by Institutions84.50% of the stock of Immunocore is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immunocore's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Immunocore are expected to decrease in the coming year, from ($1.98) to ($2.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunocore is -32.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunocore is -32.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunocore has a P/B Ratio of 5.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Immunocore's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.In answer to this issue, we have released a Special Report to the public. About Immunocore Stock (NASDAQ:IMCR)Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.Read More IMCR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMCR Stock News HeadlinesJuly 25 at 4:37 AM | finance.yahoo.comIMCR Aug 2024 30.000 call (IMCR240816C00030000)July 17, 2024 | americanbankingnews.comImmunocore Holdings plc (NASDAQ:IMCR) Short Interest Down 5.5% in JuneJuly 27, 2024 | Behind the Markets (Ad)J.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."July 17, 2024 | americanbankingnews.comBrokerages Set Immunocore Holdings plc (NASDAQ:IMCR) PT at $81.54June 1, 2024 | globenewswire.comImmunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial responseMay 31, 2024 | globenewswire.comImmunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024May 30, 2024 | globenewswire.comImmunocore to present at the Jefferies Global Healthcare ConferenceMay 29, 2024 | globenewswire.comImmunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanomaJuly 27, 2024 | Behind the Markets (Ad)J.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."May 24, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Merus (MRUS) and Immunocore Holdings (IMCR)May 24, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Cingulate Inc (CING), Indaptus Therapeutics (INDP) and Immunocore Holdings (IMCR)May 24, 2024 | barrons.comCancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know.May 22, 2024 | markets.businessinsider.comOptimistic Buy Rating for Immunocore Holdings Amid Promising Brenetafusp Study and Strategic DevelopmentsMay 18, 2024 | investing.comImmunocore Holdings PLC (IMCR)May 15, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: OptimizeRx (OPRX), Immunocore Holdings (IMCR) and Acadia Healthcare (ACHC)May 11, 2024 | finance.yahoo.comAnalysts Have Made A Financial Statement On Immunocore Holdings plc's (NASDAQ:IMCR) First-Quarter ReportMay 10, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Immunocore Holdings (IMCR), Warby Parker (WRBY) and Ocular Therapeutix (OCUL)May 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Immunocore Holdings on Strong KIMMTRAK Sales and Promising Pipeline GrowthSee More Headlines Receive IMCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunocore and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMCR CUSIPN/A CIK1671927 Webwww.immunocore.com Phone44-12-3543-8600FaxN/AEmployees320Year FoundedN/APrice Target and Rating Average Stock Price Target$82.75 High Stock Price Target$100.00 Low Stock Price Target$66.00 Potential Upside/Downside+107.2%Consensus RatingModerate Buy Rating Score (0-4)2.93 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($1.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-55,290,000.00 Net Margins-22.60% Pretax Margin-24.91% Return on Equity-16.54% Return on Assets-8.75% Debt Debt-to-Equity Ratio1.22 Current Ratio5.96 Quick Ratio5.94 Sales & Book Value Annual Sales$265.27 million Price / Sales7.53 Cash FlowN/A Price / Cash FlowN/A Book Value$7.42 per share Price / Book5.38Miscellaneous Outstanding Shares50,012,000Free Float45,461,000Market Cap$2.00 billion OptionableOptionable Beta0.74 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Bahija Jallal Ph.D. (Age 63)CEO & Executive Director Comp: $1.38MMr. Brian R. Di Donato M.B.A. (Age 57)CFO & Head of Strategy Comp: $654.46kMs. Tina St. Leger (Age 56)Chief Human Resources Officer Comp: $509.12kDr. David Berman M.D. (Age 53)Ph.D., Head of Research & Development Comp: $796.62kMr. John Trainer M.B.A. (Age 50)SVP & Chief Operating Officer Mr. John Goll IIISVP, Finance & Chief Accounting OfficerMs. Annelise Vuidepot Ph.D.CTO and Head of Pipeline & Platform ResearchMr. Sean D. Buckley (Age 41)VP & Chief Information Officer Clayton RobertsonHead of Investor RelationsMs. Lily Margaret HepworthGeneral Counsel & Company SecretaryMore ExecutivesKey CompetitorsRevolution MedicinesNASDAQ:RVMDSummit TherapeuticsNASDAQ:SMMTElanco Animal HealthNYSE:ELANKrystal BiotechNASDAQ:KRYSOrganon & Co.NYSE:OGNView All CompetitorsInsiders & InstitutionsHennion & Walsh Asset Management Inc.Bought 1,390 shares on 7/20/2024Ownership: 0.045%SG Americas Securities LLCBought 152,207 shares on 7/12/2024Ownership: 0.321%CWM LLCSold 16,919 shares on 7/10/2024Ownership: 0.003%DNB Asset Management ASBought 1,868 shares on 7/5/2024Ownership: 0.014%Tidal Investments LLCBought 6,510 shares on 5/17/2024Ownership: 0.013%View All Insider TransactionsView All Institutional Transactions IMCR Stock Analysis - Frequently Asked Questions How have IMCR shares performed this year? Immunocore's stock was trading at $68.32 at the beginning of 2024. Since then, IMCR shares have decreased by 41.3% and is now trading at $40.13. View the best growth stocks for 2024 here. How were Immunocore's earnings last quarter? Immunocore Holdings plc (NASDAQ:IMCR) announced its earnings results on Wednesday, May, 8th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.37) by $0.12. The company's quarterly revenue was up 27.6% compared to the same quarter last year. When did Immunocore IPO? Immunocore (IMCR) raised $199 million in an initial public offering on Friday, February 5th 2021. The company issued 8,300,000 shares at a price of $23.00-$25.00 per share. Goldman Sachs, J.P. Morgan and Jefferies served as the underwriters for the IPO. Who are Immunocore's major shareholders? Immunocore's top institutional investors include SG Americas Securities LLC (0.32%), Hennion & Walsh Asset Management Inc. (0.05%), DNB Asset Management AS (0.01%) and CWM LLC. View institutional ownership trends. How do I buy shares of Immunocore? Shares of IMCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IMCR) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunocore Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunocore With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
